Does insurance cover tirzepatide? Sometimes. Mounjaro, the brand used for type 2 diabetes, is commonly covered when a plan's clinical criteria are met, usually after prior authorization. Zepbound coverage for obesity or obstructive sleep apnea varies much more, and many employer plans exclude weight-management drugs. Compounded tirzepatide is generally self-pay rather than billed to insurance.

The decisive details are the brand, the diagnosis on the prescription, the plan's formulary, and the formulation being dispensed. A benefit representative saying “tirzepatide is covered” is not enough to predict what a claim will cost or whether it will be paid.

Does insurance cover tirzepatide as Mounjaro or Zepbound?

Insurance treats Mounjaro and Zepbound as separate products even though both contain tirzepatide. Mounjaro is labeled for type 2 diabetes. Zepbound is labeled for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Plans generally make coverage decisions by product and indication, not by molecule alone.

The gap is visible in claims and formulary research:

  • For diabetes coverage, a 2025 JAMA analysis of Medicare Part D formularies found that 96.2% of beneficiaries had formulary coverage for tirzepatide. Prior authorization for GLP-1 drugs was almost universal in 2025. Those numbers describe Part D, not every commercial plan, but they show why Mounjaro is often covered with conditions.
  • For weight management, a 2026 JAMA Health Forum study examined 5,787 UnitedHealthcare-administered employer plans. Only 14.9% covered GLP-1 drugs for weight loss in December 2024. The study did not measure self-pay purchases, but it documents how common the employer-plan exclusion was.

Promise's tirzepatide is dispensed as a compounded medication, which is different from FDA-approved brand products: the formulation offered here is not FDA-approved. Mounjaro, Zepbound, and a compounded prescription are therefore not interchangeable insurance claims.

What prior authorization actually decides

Prior authorization is the insurer's clinical and administrative review before it agrees to pay. For Mounjaro, the plan may ask for a documented type 2 diabetes diagnosis, recent laboratory results, and a record of other diabetes medications. For Zepbound, criteria may include the covered indication, BMI, related conditions, prior treatment, or participation in a weight-management program. The exact checklist belongs to the plan.

Five questions produce a more useful answer than “Is tirzepatide covered?”

  1. Is Mounjaro or Zepbound on the formulary for this diagnosis?
  2. Does it require prior authorization or step therapy?
  3. What records must the prescriber submit?
  4. What is the estimated cost for one 28-day fill after the deductible?
  5. Must the prescription use a specific pharmacy or mail-order service?

A formulary listing is not a promise that a claim will be paid. Coverage can also change at renewal. If Zepbound is excluded, a semaglutide brand may have different coverage, but it is a different medication with its own clinical criteria; the prescriber decides whether an alternative is appropriate.

Medicare tirzepatide coverage changed in 2026

As of August 25, 2026, the statutory Part D exclusion still applies to drugs used solely for weight loss. The important change is the Medicare GLP-1 Bridge, which began July 1, 2026 and runs through December 31, 2027. It operates outside the Part D benefit.

For eligible beneficiaries, the Bridge includes Zepbound KwikPen for weight management, requires provider-submitted prior authorization, and uses a $50 copay. CMS applies BMI and comorbidity criteria. The Zepbound single-dose vial and single-dose pen are not included in the Bridge, and its copay does not count toward Part D out-of-pocket totals. The Bridge also includes Wegovy, the branded semaglutide option, which has separate clinical and coverage criteria from Zepbound.

The route is different when tirzepatide is prescribed for a Part D-coverable indication. Mounjaro for type 2 diabetes and Zepbound for moderate-to-severe obstructive sleep apnea in an adult with obesity go through the Part D plan, including its formulary or exception process, rather than through the Bridge. This is why an answer based only on “Medicare” or only on the drug name can be wrong.

Savings cards and LillyDirect are not insurance

Lilly's terms, checked August 25, 2026, separate commercially insured patients from government-program beneficiaries. The Zepbound savings program says eligible patients with commercial coverage for the single-dose pen may pay as little as $25, subject to monthly and annual limits. Other commercial-insurance situations have different offers. Medicare, Medicaid, VA, and other government-program beneficiaries are excluded from that card, and its 2026 terms expire December 31.

For patients paying without insurance, LillyDirect lists Zepbound vials at $299 for 2.5 mg, $399 for 5 mg, and $449 for higher doses when program refill terms are met. Those are manufacturer self-pay prices, not copays, and terms can change. The existing tirzepatide cost guide owns the full route-by-route price comparison.

Why compounded tirzepatide is usually self-pay

Compounded tirzepatide is generally not processed as a covered brand claim. The tradeoff is straightforward: the patient pays directly, but the price is known without waiting for a formulary decision or prior authorization. Promise's current price appears in the product card rather than in this article.

Self-pay does not remove the prescription gate. At Promise, a licensed provider reviews every request and may prescribe only when medically appropriate; not everyone qualifies. If prescribed, the service includes clinical review, pharmacy dispensing, shipping, and follow-up rather than just an unverified vial.

Compounded tirzepatide explains what the pharmacy-prepared formulation is and how it differs from a brand product. Regulatory status is one part of that conversation; a licensed provider may still prescribe a compounded formulation when appropriate, and that decision belongs to the patient and the doctor. For eligible medical expenses, the separate guide to using HSA or FSA funds for GLP-1 care covers documentation and plan rules without promising reimbursement.

The honest comparison is between the amount insurance would actually leave you to pay after authorization and the complete self-pay service. A low advertised copay may not apply before a deductible, while a higher fixed price may include care that a retail prescription does not.

Bring the exact brand, indication, formulation, and pharmacy route into that comparison. Those four details decide whether “covered” turns into a paid claim or another round of paperwork.